查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589848

法布瑞氏症治疗市场：依治疗类型、药物、给药途径- 全球预测 2025-2030

Fabry Disease Treatment Market by Treatment Type (Chaperone Treatment, Enzyme Replacement Therapy, Organ-Specific Treatment), Drugs (Agalsidase Beta, Migalastat, Pipeline Drugs), Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

法布瑞氏症治疗市场2023年估值为25亿美元，预计2024年将达27.1亿美元，复合年增长率为8.47%，预计2030年将达44.1亿美元。

法布瑞氏症治疗市场范围包括旨在控制这种罕见遗传性溶小体贮积症症状和减缓疾病进展的治疗解决方案。这包括酵素替代疗法、Chaperone疗法、基材减少疗法和潜在的基因疗法，市场扩展到特种药物和生物技术创新。法布瑞氏症有效治疗的需求源自于需要缓解疼痛、肾衰竭和心臟併发症等严重症状，并显着改善患者的生活品质。这些治疗方法适用于医院、专科治疗中心和居家医疗机构，最终用途包括患有这种疾病的儿童和成人患者。市场洞察表明，关键因素包括由于诊断改进而导致患病率上升、促进早期疗育的患者意识提高以及大型生物製药公司为扩大治疗选择而对研发进行的大量投资，这已成为主要的成长要素。此外，孤儿药的监管激励措施正在促进该市场的创新。

主要市场统计
基准年[2023] 25亿美元
预测年份 [2024] 27.1亿美元
预测年份 [2030] 44.1亿美元
复合年增长率（%） 8.47%

潜在的商机在于基因治疗和个人化医疗的进步，提供变革性的治疗方法。及时的建议包括利用策略合作伙伴关係并专注于现实世界的资料收集，以提高治疗效果和患者结果。然而，高昂的治疗成本、有限的患者群体和严格的监管要求等挑战正在限制市场的成长。此外，罕见疾病治疗的核准和报销政策的不可预测性使市场动态更加复杂。创新和研究应着重于优化治疗方法和开发新型药物传输技术，例如奈米颗粒和基于 CRISPR 的解决方案，以提高生物有效性并减少副作用。法布瑞氏症治疗市场的特点是其特殊性，需要利基行销策略并培养持续临床开发的环境，以利用科学突破。

市场动态：快速发展的法布瑞氏症治疗市场的关键市场洞察

供需的动态交互作用正在改变法布瑞氏症治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 对传讯RNA治疗方法法布瑞氏症的需求不断增长
    • 临床试验数量增加
    • 提高遗传疾病的盛行率和认识
  • 市场限制因素
    • 对法布瑞氏症治疗进展缺乏认识
  • 市场机会
    • 法布瑞氏症治疗的持续研究与开发
    • 新兴国家医疗保健支出增加和基础设施改善
  • 市场挑战
    • 某些国家对引进新技术的限制

波特五力：开拓法布瑞氏症治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解法布瑞氏症治疗市场的外在影响

外部宏观环境因素在塑造法布瑞氏症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解法布瑞氏症治疗市场的竞争状况

对法布瑞氏症治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵法布瑞氏症治疗市场供应商的绩效评估

FPNV定位矩阵是评估法布瑞氏症治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了法布瑞氏症治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，法布瑞氏症治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 作为法布瑞氏症的治疗方法，对传讯RNA的需求增加
      • 临床试验增加
      • 遗传疾病的发生率和认识不断提高
    • 抑制因素
      • 对法布瑞氏症治疗进展缺乏认识
    • 机会
      • 法布瑞氏症治疗的持续研究与开发
      • 新兴国家医疗保健成本上升和基础设施改善
    • 任务
      • 某些国家对引进新技术的限制
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的法布瑞氏症治疗市场

  • Chaperone治疗
  • 酵素替代疗法
  • 器官特异性治疗
  • 基材减少疗法

第七章 法布瑞氏症药物治疗市场

  • 阿加糖酶β
  • 米加司他
  • 管道药品

第八章法布瑞氏症治疗市场：依给药途径

  • 静脉
  • 口服

第九章 美洲法布瑞氏症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区法布瑞氏症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲法布瑞氏症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amicus Therapeutics Inc.
  • Avrobio Inc.
  • BioMarin
  • Biosidus SA
  • Digestive Care, Inc.
  • GlaxoSmithKline PLC
  • Idorsia Pharmaceuticals Ltd.
  • ISU Abxis Co Ltd.
  • JCR Pharmaceuticals Co Ltd.
  • Leadiant Biosciences, Inc.
  • Nestle Health Science
  • Pfizer Inc.
  • Protalix Biotherapeutics Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4348D129FB16

The Fabry Disease Treatment Market was valued at USD 2.50 billion in 2023, expected to reach USD 2.71 billion in 2024, and is projected to grow at a CAGR of 8.47%, to USD 4.41 billion by 2030.

The scope of the Fabry disease treatment market encompasses therapeutic solutions aimed at managing symptoms and slowing disease progression for this rare genetic lysosomal storage disorder. This includes enzyme replacement therapies, chaperone therapies, substrate reduction therapies, and potentially gene therapies, with the market extending to specialty pharmaceuticals and biotechnological innovations. The necessity for effective Fabry disease treatments stems from the need to alleviate severe symptoms such as pain, renal failure, and cardiac complications, significantly improving patients' quality of life. These treatments find application across hospitals, specialized treatment centers, and homecare settings, with end-use scope including both pediatric and adult patient populations affected by the disease. Market insights reveal key growth factors including increasing prevalence rates owing to improved diagnostics, heightened patient awareness facilitating early intervention, and substantial R&D investments from major biopharmaceutical companies aiming to expand therapeutic options. Moreover, regulatory incentives for orphan drugs foster innovation within this market.

KEY MARKET STATISTICS
Base Year [2023] USD 2.50 billion
Estimated Year [2024] USD 2.71 billion
Forecast Year [2030] USD 4.41 billion
CAGR (%) 8.47%

Potential opportunities lie in the advancement of gene therapy and personalized medicine, offering transformative treatment modalities. Timely recommendations include leveraging strategic collaborations and focusing on real-world data collection to enhance therapeutic efficacy and patient outcomes. However, challenges such as high treatment costs, limited patient populations, and rigorous regulatory requirements pose constraints on market growth. Furthermore, the unpredictable nature of rare disease treatment approvals and reimbursement policies further complicate market dynamics. Innovation and research should pivot towards optimizing treatment regimens and developing novel drug delivery technologies, such as nanoparticle and CRISPR-based solutions, to improve bioavailability and reduce adverse effects. The Fabry disease treatment market is characterized by its specialized nature, necessitating niche marketing strategies and fostering an environment of continuous clinical development to capitalize on scientific breakthroughs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fabry Disease Treatment Market

The Fabry Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing demand for messenger RNA as a treatment modality for Fabry disease
    • Increasing number of clinical trials
    • Growing incidences of genetic disorders and increasing awareness
  • Market Restraints
    • Lack of awareness about advancements with respect to treatments for Fabry disease
  • Market Opportunities
    • Ongoing research and development for the treatment of Fabry disease
    • Increasing healthcare expenditure and improving infrastructure in emerging economies
  • Market Challenges
    • Limitations in adopting new technologies in certain countries

Porter's Five Forces: A Strategic Tool for Navigating the Fabry Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fabry Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fabry Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fabry Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fabry Disease Treatment Market

A detailed market share analysis in the Fabry Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fabry Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fabry Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fabry Disease Treatment Market

A strategic analysis of the Fabry Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fabry Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Amicus Therapeutics Inc., Avrobio Inc., BioMarin, Biosidus S.A., Digestive Care, Inc., GlaxoSmithKline PLC, Idorsia Pharmaceuticals Ltd., ISU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Leadiant Biosciences, Inc., Nestle Health Science, Pfizer Inc., Protalix Biotherapeutics Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Fabry Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Chaperone Treatment, Enzyme Replacement Therapy, Organ-Specific Treatment, and Substrate Reduction Therapy.
  • Based on Drugs, market is studied across Agalsidase Beta, Migalastat, and Pipeline Drugs.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for messenger RNA as a treatment modality for Fabry disease
      • 5.1.1.2. Increasing number of clinical trials
      • 5.1.1.3. Growing incidences of genetic disorders and increasing awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness about advancements with respect to treatments for Fabry disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for the treatment of Fabry disease
      • 5.1.3.2. Increasing healthcare expenditure and improving infrastructure in emerging economies
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations in adopting new technologies in certain countries
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fabry Disease Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Chaperone Treatment
  • 6.3. Enzyme Replacement Therapy
  • 6.4. Organ-Specific Treatment
  • 6.5. Substrate Reduction Therapy

7. Fabry Disease Treatment Market, by Drugs

  • 7.1. Introduction
  • 7.2. Agalsidase Beta
  • 7.3. Migalastat
  • 7.4. Pipeline Drugs

8. Fabry Disease Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Americas Fabry Disease Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Fabry Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Fabry Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amicus Therapeutics Inc.
  • 2. Avrobio Inc.
  • 3. BioMarin
  • 4. Biosidus S.A.
  • 5. Digestive Care, Inc.
  • 6. GlaxoSmithKline PLC
  • 7. Idorsia Pharmaceuticals Ltd.
  • 8. ISU Abxis Co Ltd.
  • 9. JCR Pharmaceuticals Co Ltd.
  • 10. Leadiant Biosciences, Inc.
  • 11. Nestle Health Science
  • 12. Pfizer Inc.
  • 13. Protalix Biotherapeutics Inc.
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. FABRY DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. FABRY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FABRY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FABRY DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ORGAN-SPECIFIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY AGALSIDASE BETA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY MIGALASTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PIPELINE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023